arrow
L

Laurence Buisseret

universite libre de bruxelles
H指数:28
被引数:6,306

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2− breast cancer: a randomized phase 2 trial

durvalumab和oleclumab新辅助立体定向放射治疗ER HER2 − 乳腺癌: 一项随机2期试验

2026-06-250
OAAI
“When Immunity Backfires: meta-analysis on Sarcoidosis Reactivation in Cancer Patients Treated with Immune Checkpoint Inhibitors”

“当免疫力适得其反:免疫检查点抑制剂治疗癌症患者中肉芽肿病复发的荟萃分析”

2026-03-200
PRE
Immuno-radiotherapy enhances tumor control and induces abscopal responses in a humanized mouse model

免疫放射疗法增强肿瘤控制并诱导全身反应(abscopal responses)在人类化小鼠模型中

2026-03-110
OAAI
Association Between Alcohol Consumption and Breast Cancer Incidence and Prognosis: A Systematic Review and Meta-Analysis

酒精摄入与乳腺癌发病率及预后的关系:一项系统评价和Meta分析

2026-02-050
OAAI
Personalized ctDNA detection and genomic profiling in the NeoRHEA Study

个性化循环肿瘤DNA检测和基因组分析在NeoRHEA研究中

2025-12-050
OAAI
Palbociclib and endocrine therapy diminish adaptive anti-tumor immunity in early breast cancer: The NeoRHEA phase 2 study

Palbociclib和内分泌疗法减弱早期乳腺癌的适应性抗肿瘤免疫:NeoRHEA 2期研究

2025-11-260
OAAI
Adapting radiation therapy to immunotherapy: Delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase II Neo-CheckRay trial
2025-05-010
PRE
Spatial transcriptomics reveals substantial heterogeneity in triple-negative breast cancer with potential clinical implications
2024-11-260
OAAI
Spatial predictors of pathologic complete response to neoadjuvant chemotherapy using imaging mass cytometry in the IMMUcan TNBC cohort

使用成像质谱细胞术评估IMMUcan TNBC队列中对新辅助化疗达到病理完全缓解的空间预测因子

2024-09-010
PRE
Single-cell RNA sequencing reveals tumor heterogeneity and potential mechanisms of response/resistance in breast cancer treated with neoadjuvant therapy

单细胞RNA测序揭示了接受新辅助治疗的乳腺癌中的肿瘤异质性以及反应/耐药性的潜在机制

2024-09-010
PRE
Characterization of tertiary lymphoid structures and its association with response to immune checkpoint inhibitors in triple negative breast cancer using spatial transcriptomics
2024-05-020
PRE
The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumab

免疫治疗生物标志物的漫长而曲折的道路: 对使用pembrolizumab治疗的三阴性乳腺癌患者样本的回顾性分析

2024-05-010
OAAI
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial (vol 14, 7018, 2023)
2023-12-120
OAAI
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial
2023-11-025
OAAI
Deep learning-based prediction of pathologic complete response to neoadjuvant therapy in breast cancer using H&E images and RNA-Seq in the IMMUcan study

在IMMUcan研究中使用H & E图像和rna-seq对乳腺癌新辅助治疗的病理完全反应进行基于深度学习的预测

2023-10-010
OA